We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Autoimmune Industry Characterized by High Demand and Competition

By LabMedica International staff writers
Posted on 27 Oct 2016
The multi-billion dollar autoimmune IVD testing market is growing at a faster pace than the IVD market as a whole. This high demand is attracting a number of IVD manufacturers to the market, including some of the top names in the business, and its growth will continue to be driven by the efforts of the players in the industry.

These are the latest findings of Kalorama Information, (New York, NY, USA), an independent medical market research firm.

Image: Crohn’s disease is one of the most common chronic illnesses (Photo courtesy of SPL).
Image: Crohn’s disease is one of the most common chronic illnesses (Photo courtesy of SPL).

Autoimmune disease refers to a varied group of over 80 chronic illnesses involving almost every human organ system that is characterized by the immune system recognizing the self as non-self, and the body attacking itself. Some prominent autoimmune diseases include Rheumatoid arthritis, Crohn’s disease, IBD, celiac disease, lupus, thyroid disease and others.

Autoimmune disease is a competitive area of clinical testing with various competitors and categories of different revenue potential. In terms of test products, a substantial amount of sameness is present in the market, with a number of "me-too" tests, although that competition should resolve soon. Given the continued medical discovery of autoimmune conditions, the R&D of accurate tests to identify specific diseases creates potential revenue opportunities that could exist for future tests and competitors.

Diagnostic companies continue to gradually improve their fully automated platforms. Additionally, a number of companies are developing innovative new platforms. In view of the demand for these autoimmune tests, they have been reformulated for automated analyzers where the cost per test is traditionally low.

The growth in the autoimmune IVD testing market is expected to be driven by Type 1 diabetes (HbA1c), gastrointestinal disorders and other diseases. Moreover, among the aging population, the number of aging women will be higher, as a result of which women are likely to be affected by autoimmune diseases more than men. This is expected to create a large demographic that will benefit from novel and sophisticated autoimmune IVD diagnostic testing.

"The scourge of autoimmune conditions and the age of population, particularly the female population most affected by these diseases has spawn a fair number of diagnostic test products," said Bruce Carlson, Publisher of Kalorama Information. "There is room for more, and small test makers are finding opportunity exists for discovery and advancement in this arena. Competition is a factor that will boost a market; lots of companies means more purchases, and thankfully more options for providers and patients."

Related Links:
Kalorama Information


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Xylazine Immunoassay Test
Xylazine ELISA

Latest Industry News

ECCMID Congress Name Changes to ESCMID Global

Bosch and Randox Partner to Make Strategic Investment in Vivalytic Analysis Platform

Siemens to Close Fast Track Diagnostics Business